Sun Pharmaceutical Industries Ltd management interview: Sun Pharma Reports Mixed Q2FY27 Performance | CNBC TV18
CNBC-TV18, 2026-11-02. Video: https://www.youtube.com/watch?v=Y57PH6zlJ6M
- Quarterly revenue: Revenue grew around 12-odd percent, versus expected 9-odd percent, while global innovative business growth slowed to 6.9% from double-digit growth in previous quarters.
- Ilumya outlook: US sales faced headwinds from purchasing decisions and pricing pressures; Sun has strengthened its dermatology and immunology teams and expects sales to get back on track in the coming months. The new psoriatic arthritis approval should support sales, but the company gave no specific guidance for the additional indication, against $796 million in FY26 sales.
- Company guidance: Sun said it would maintain the overall growth indications and guidance provided at the beginning of the year; it did not give a separate growth timeline for the global innovative business.
- New US products: Feedback on Unloxcyt and Leqselvi has been encouraging. Sun is focused on expanding prescriber reach and experience for Unloxcyt, and on Leqselviâs hair re-growth speed and positive patient experience, while pursuing the commercial plans originally envisaged.